In a bid toward greater transparency, the U.S. Food and Drug Administration earlier this month launched a dashboard containing preliminary notices sent to companies, universities, and researchers that failed to register clinical trials or report study results.
The agency has so far sent about 120 so-called pre-notices indicating a clinical trial sponsor or investigator failed to comply with a federal law that requires such steps. If follow-up does not occur, the FDA can issue a non-compliance notice and seek penalties. Among those that received a pre-notice were Novartis, Bausch and Lomb, and the Georgetown University Medical Center.
The move comes amid growing complaints that compliance is lacking.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect